Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications

Abstract Significance: Enhanced levels of reactive oxygen species (ROS) have been associated with different disease states. Most attempts to validate and exploit these associations by chronic antioxidant therapies have provided disappointing results. Hence, the clinical relevance of ROS is still largely unclear. Recent Advances: We are now beginning to understand the reasons for these failures, which reside in the many important physiological roles of ROS in cell signaling. To exploit ROS therapeutically, it would be essential to define and treat the disease-relevant ROS at the right moment and leave physiological ROS formation intact. This breakthrough seems now within reach. Critical Issues: Rather than antioxidants, a new generation of protein targets for classical pharmacological agents includes ROS-forming or toxifying enzymes or proteins that are oxidatively damaged and can be functionally repaired. Future Directions: Linking these target proteins in future to specific disease states and providing in each case proof of principle will be essential for translating the oxidative stress concept into the clinic. Antioxid. Redox Signal. 23, 1171–1185.

[1]  A. Cuadrado,et al.  Antioxidants in Translational Medicine , 2015, Antioxidants & redox signaling.

[2]  Tilman Grune,et al.  Clinical Relevance of Biomarkers of Oxidative Stress , 2015, Antioxidants & redox signaling.

[3]  R. Fryer,et al.  A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat , 2015, BMC Pharmacology and Toxicology.

[4]  H. Schmidt,et al.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. , 2015, Antioxidants & redox signaling.

[5]  K. Anstrom,et al.  Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study , 2015, Circulation.

[6]  A. Majeed,et al.  Zinc: indications in brain disorders , 2015, Fundamental & clinical pharmacology.

[7]  J. Stasch,et al.  Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. , 2015, Current opinion in pharmacology.

[8]  Raynoo Thanan,et al.  Oxidative Stress and Its Significant Roles in Neurodegenerative Diseases and Cancer , 2014, International journal of molecular sciences.

[9]  F. StoverJohn,et al.  Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). , 2014 .

[10]  Sanjiv J. Shah,et al.  Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) , 2014, European journal of heart failure.

[11]  N. Kaludercic,et al.  Reactive oxygen species and redox compartmentalization , 2014, Front. Physiol..

[12]  N. Kaludercic,et al.  Monoamine oxidases as sources of oxidants in the heart. , 2014, Journal of molecular and cellular cardiology.

[13]  J. Lambeth,et al.  Nox4: A Hydrogen Peroxide-Generating Oxygen Sensor , 2014, Biochemistry.

[14]  Chun-Peng Liao,et al.  Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. , 2014, The Journal of clinical investigation.

[15]  R. Touyz,et al.  NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. , 2014, Antioxidants & redox signaling.

[16]  R. Touyz,et al.  Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[17]  N. Chandel,et al.  ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.

[18]  V. Thannickal,et al.  Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox Imbalance , 2014, Science Translational Medicine.

[19]  T. Münzel,et al.  Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. , 2014, Antioxidants & redox signaling.

[20]  D. Kass,et al.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. , 2014, Antioxidants & redox signaling.

[21]  T. Ferguson,et al.  Monoamine Oxidase is a Major Determinant of Redox Balance in Human Atrial Myocardium and is Associated With Postoperative Atrial Fibrillation , 2014, Journal of the American Heart Association.

[22]  Y. Nakabeppu,et al.  Mice Heterozygous for the Xanthine Oxidoreductase Gene Facilitate Lipid Accumulation in Adipocytes , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Bressler,et al.  Interaction between the NOS3 Gene and Obesity as a Determinant of Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study , 2013, PloS one.

[24]  L. Hofbauer,et al.  NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. , 2013, The Journal of clinical investigation.

[25]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[26]  Richard F. Thompson,et al.  Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice , 2013, Proceedings of the National Academy of Sciences.

[27]  R. Brandes,et al.  Monoamine Oxidases Are Mediators of Endothelial Dysfunction in the Mouse Aorta , 2013, Hypertension.

[28]  E. Morand,et al.  Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function. , 2013, Blood.

[29]  H. Schmidt,et al.  Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. , 2013, Antioxidants & redox signaling.

[30]  K. Andrews,et al.  NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis , 2013, Circulation.

[31]  Eva Dizin,et al.  NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. , 2012, Journal of the American Society of Nephrology : JASN.

[32]  H. Schmidt,et al.  NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury , 2012, Journal of Molecular Medicine.

[33]  R. Ramsay Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. , 2012, Current topics in medicinal chemistry.

[34]  Steve D. M. Brown,et al.  A Mouse Model of Early-Onset Renal Failure Due to a Xanthine Dehydrogenase Nonsense Mutation , 2012, PloS one.

[35]  G. Filippatos,et al.  Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes , 2012, European journal of heart failure.

[36]  M. Rodríguez-Muñoz,et al.  GPCRs promote the release of zinc ions mediated by nNOS/NO and the redox transducer RGSZ2 protein. , 2012, Antioxidants & redox signaling.

[37]  Oliver Jung,et al.  Role of Nox4 in murine models of kidney disease. , 2012, Free radical biology & medicine.

[38]  H. Neumayer,et al.  Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction. , 2012, The Journal of urology.

[39]  U. Förstermann,et al.  Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina. , 2012, Biochemical and biophysical research communications.

[40]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[41]  H. Schmidt,et al.  The NOX toolbox: validating the role of NADPH oxidases in physiology and disease , 2012, Cellular and Molecular Life Sciences.

[42]  C. Kleinschnitz,et al.  The 1027th target candidate in stroke: Will NADPH oxidase hold up? , 2012, Experimental & Translational Stroke Medicine.

[43]  D. Behm,et al.  Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress , 2012, Front. Pharmacol..

[44]  K. Krause,et al.  NOX enzymes as drug targets , 2012, Cellular and Molecular Life Sciences.

[45]  K. Krause,et al.  NOX5: from basic biology to signaling and disease. , 2012, Free radical biology & medicine.

[46]  S. Blankenberg,et al.  Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase , 2011, Circulation.

[47]  H. Neumayer,et al.  Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction. , 2011, The Journal of urology.

[48]  B. Hinz,et al.  A key role for NOX4 in epithelial cell death during development of lung fibrosis. , 2011, Antioxidants & redox signaling.

[49]  J. Monks,et al.  Contribution of Xanthine Oxidoreductase to Mammary Epithelial and Breast Cancer Cell Differentiation In Part Modulates Inhibitor of Differentiation-1 , 2011, Molecular Cancer Research.

[50]  M. Rodríguez-Muñoz,et al.  NO-released zinc supports the simultaneous binding of Raf-1 and PKCγ cysteine-rich domains to HINT1 protein at the mu-opioid receptor. , 2011, Antioxidants & redox signaling.

[51]  G. Cecchini,et al.  Molecular identification of the enzyme responsible for the mitochondrial NADH‐supported ammonium‐dependent hydrogen peroxide production , 2011, FEBS letters.

[52]  C. Reggiani,et al.  Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. , 2010, Human molecular genetics.

[53]  H. Schmidt,et al.  Comparative pharmacology of chemically distinct NADPH oxidase inhibitors , 2010, British journal of pharmacology.

[54]  H. Fuchs,et al.  Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration , 2010, PLoS biology.

[55]  A. Shah,et al.  Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition , 2010, Hypertension.

[56]  D. Atochin,et al.  Endothelial nitric oxide synthase transgenic models of endothelial dysfunction , 2010, Pflügers Archiv - European Journal of Physiology.

[57]  Sonia S Anand,et al.  The impact of social determinants on cardiovascular disease. , 2010, The Canadian journal of cardiology.

[58]  P. Lapchak A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? , 2010, Expert opinion on pharmacotherapy.

[59]  L. Gaunt,et al.  Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements , 2010, European Journal of Human Genetics.

[60]  T. Meinertz,et al.  Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. , 2010, International journal of cardiology.

[61]  U. Förstermann,et al.  Pentaerythritol Tetranitrate Improves Angiotensin II–Induced Vascular Dysfunction via Induction of Heme Oxygenase-1 , 2010, Hypertension.

[62]  D. Kass,et al.  Monoamine Oxidase A–Mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload , 2010, Circulation research.

[63]  G. Bokoch,et al.  Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. , 2009, Antioxidants & redox signaling.

[64]  D. Fulton Nox5 and the regulation of cellular function. , 2009, Antioxidants & redox signaling.

[65]  T. Leto,et al.  Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. , 2009, Antioxidants & redox signaling.

[66]  J. Stasch,et al.  Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation , 2009, Circulation research.

[67]  F. Martinez,et al.  NADPH Oxidase-4 Mediates Myofibroblast Activation and Fibrogenic Responses to Lung Injury , 2009, Nature Medicine.

[68]  R. Holmdahl,et al.  The protective role of ROS in autoimmune disease. , 2009, Trends in immunology.

[69]  F. Vanmolkot,et al.  Does the Unfavorable Pharmacokinetic and Pharmacodynamic Profile of the iNOS Inhibitor GW273629 Lead to Inefficacy in Acute Migraine? , 2009, Journal of clinical pharmacology.

[70]  M. Giorgio,et al.  Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase , 2009, Basic Research in Cardiology.

[71]  D. Harrison,et al.  Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. , 2008, Journal of the American College of Cardiology.

[72]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[73]  K. Krause,et al.  Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase , 2008, Seminars in Immunopathology.

[74]  Steven R Steinhubl,et al.  Why have antioxidants failed in clinical trials? , 2008, The American journal of cardiology.

[75]  Songnian Hu,et al.  The monoamine oxidase B gene exhibits significant association to ADHD , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[76]  R. Busse,et al.  Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant , 2008, Hypertension.

[77]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[78]  K. Krause,et al.  NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. , 2007, The Biochemical journal.

[79]  W. Seeger,et al.  Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.

[80]  T. Kawahara,et al.  Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes , 2007, BMC Evolutionary Biology.

[81]  L. Donahue,et al.  Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2. , 2007, Molecular endocrinology.

[82]  K. Krause,et al.  NOX1 Deficiency Protects From Aortic Dissection in Response to Angiotensin II , 2007, Hypertension.

[83]  Paul L Huang,et al.  Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. , 2007, Cardiovascular research.

[84]  G. Opala,et al.  Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. , 2007, Parkinsonism & related disorders.

[85]  F. Van de Werf,et al.  Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. , 2007, JAMA.

[86]  Eden R Martin,et al.  Family‐based case–control study of MAOA and MAOB polymorphisms in Parkinson disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[87]  R. Busse,et al.  Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. , 2006, Free radical biology & medicine.

[88]  H. Shimokawa,et al.  Development of genetically engineered mice lacking all three nitric oxide synthases. , 2006, Journal of pharmacological sciences.

[89]  S. Neubauer,et al.  5-Methyltetrahydrofolate Rapidly Improves Endothelial Function and Decreases Superoxide Production in Human Vessels: Effects on Vascular Tetrahydrobiopterin Availability and Endothelial Nitric Oxide Synthase Coupling , 2006, Circulation.

[90]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[91]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[92]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[93]  C. Sigmund,et al.  Inactivation of NADPH oxidase organizer 1 Results in Severe Imbalance , 2006, Current Biology.

[94]  K. Krause,et al.  Decreased blood pressure in NOX1‐deficient mice , 2006, FEBS letters.

[95]  E. Masini,et al.  Oxidative Stress by Monoamine Oxidase Mediates Receptor-Independent Cardiomyocyte Apoptosis by Serotonin and Postischemic Myocardial Injury , 2005, Circulation.

[96]  D. Sorescu,et al.  NAD(P)H Oxidase 4 Mediates Transforming Growth Factor-β1–Induced Differentiation of Cardiac Fibroblasts Into Myofibroblasts , 2005, Circulation research.

[97]  D. Weiss,et al.  Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice , 2005, Circulation.

[98]  Masato Matsuki,et al.  Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice , 2005, Circulation.

[99]  Denise Lau,et al.  Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[100]  U. Zabel,et al.  Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[101]  A. Mattevi,et al.  Structure and mechanism of monoamine oxidase. , 2004, Current medicinal chemistry.

[102]  A. Segal,et al.  The NADPH oxidase of professional phagocytes--prototype of the NOX electron transport chain systems. , 2004, Biochimica et biophysica acta.

[103]  Mario Engelmann,et al.  Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. , 2004, Nitric oxide : biology and chemistry.

[104]  U. Heinzmann,et al.  Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. , 2004, Genes & development.

[105]  T. Münzel,et al.  ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.

[106]  M. Currie,et al.  A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[107]  A. Parini,et al.  Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. , 2003, American journal of physiology. Heart and circulatory physiology.

[108]  B. Hoyos,et al.  Zinc Release from Protein Kinase C as the Common Event during Activation by Lipid Second Messenger or Reactive Oxygen* , 2002, The Journal of Biological Chemistry.

[109]  Chunxiang Zhang,et al.  Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.

[110]  R. Hotchkiss,et al.  Myeloperoxidase produces nitrating oxidants in vivo. , 2002, The Journal of clinical investigation.

[111]  J. Stasch,et al.  Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies , 2002, British journal of pharmacology.

[112]  D. Bullard,et al.  Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. , 2001, The Journal of clinical investigation.

[113]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[114]  K. Krause,et al.  A Ca2+-activated NADPH Oxidase in Testis, Spleen, and Lymph Nodes* , 2001, The Journal of Biological Chemistry.

[115]  T. Gori,et al.  Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance: A Human In Vivo Study , 2001, Circulation.

[116]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition , 2001 .

[117]  D. Harrison,et al.  Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.

[118]  T. Meinertz,et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus , 2000, Diabetologia.

[119]  A. Kettle,et al.  Biomarkers of myeloperoxidase-derived hypochlorous acid. , 2000, Free radical biology & medicine.

[120]  E. Klann,et al.  Superoxide-induced Stimulation of Protein Kinase C via Thiol Modification and Modulation of Zinc Content* , 2000, The Journal of Biological Chemistry.

[121]  S. Hazen,et al.  Myeloperoxidase-generated oxidants and atherosclerosis. , 2000, Free radical biology & medicine.

[122]  Jing Fang,et al.  Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .

[123]  A. Morris,et al.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. , 2000, Hypertension.

[124]  B. Mayer,et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. , 2000, Circulation research.

[125]  E. Paykel,et al.  Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. , 1999, American journal of medical genetics.

[126]  P. Wang,et al.  Current trends in the development of nitric oxide donors. , 1999, Current pharmaceutical design.

[127]  A. Kettle,et al.  Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. , 1998, Blood.

[128]  H Ishii,et al.  Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[129]  R. T. Miller,et al.  Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. , 1997, Biochemistry.

[130]  T. Nishino,et al.  The Conversion from the Dehydrogenase Type to the Oxidase Type of Rat Liver Xanthine Dehydrogenase by Modification of Cysteine Residues with Fluorodinitrobenzene* , 1997, The Journal of Biological Chemistry.

[131]  J. Zweier,et al.  Direct measurement of nitric oxide generation from nitric oxide synthase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[132]  J. Saura,et al.  Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain , 1997, Neurobiology of Aging.

[133]  E. Paykel,et al.  Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. , 1996, Human molecular genetics.

[134]  R. Murray,et al.  Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. , 1995, American journal of medical genetics.

[135]  R. Hille,et al.  Xanthine oxidase and xanthine dehydrogenase , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[136]  U. Walter,et al.  NO at work , 1994, Cell.

[137]  J. Heinecke,et al.  Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. , 1994, The Journal of biological chemistry.

[138]  M. Nelen,et al.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. , 1993, Science.

[139]  M. Nelen,et al.  X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. , 1993, American journal of human genetics.

[140]  A. Chapelle,et al.  Marked Amine and Amine Metabolite Changes in Norrie Disease Patients with an X‐Chromosomal Deletion Affecting Monoamine Oxidase , 1990, Journal of neurochemistry.

[141]  G. Elion,et al.  The purine path to chemotherapy , 1989, In Vitro Cellular & Developmental Biology.

[142]  A. Chapelle,et al.  Monoamine oxidase deficiency in males with an X chromosome deletion , 1989, Neuron.

[143]  J. McCord,et al.  Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.

[144]  B. Winblad,et al.  Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. , 1980, Life sciences.

[145]  S. Klebanoff Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.

[146]  E. Chiu,et al.  Platelet monoamine oxidase activity in Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[147]  S. Klebanoff Myeloperoxidase-Halide-Hydrogen Peroxide Antibacterial System , 1968, Journal of bacteriology.

[148]  U. Ungerstedt,et al.  Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). , 2014, Journal of neurotrauma.

[149]  Céline Guilbeau-Frugier,et al.  p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. , 2013, Antioxidants & redox signaling.

[150]  R. Touyz,et al.  Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. , 2012, Basic & clinical pharmacology & toxicology.

[151]  J. Shih,et al.  Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. , 2011, International review of neurobiology.

[152]  X. Estivill,et al.  Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB , 2009, Molecular Psychiatry.

[153]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[154]  M. Dinauer,et al.  Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. , 2006, Cellular signalling.

[155]  D. T. Harwood,et al.  Chlorine transfer between glycine, taurine, and histamine: reaction rates and impact on cellular reactivity. , 2004, Free radical biology & medicine.

[156]  W. Dröge Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[157]  V. Massey FLAVOPROTEIN STRUCTURE AND MECHANISM , 1995 .

[158]  A. Clow,et al.  Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase? , 1993, Advances in neurology.

[159]  D. Murphy,et al.  Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. , 1992, American journal of medical genetics.